Journal List > J Korean Med Assoc > v.53(6) > 1042288

Kim: The Pharmacotherapy of Inflammatory Bowel Disease in Child and Adolescence


The importance of pediatric inflammatory bowel disease (IBD) has grown significantly, for the incidence of pediatric inflammatory bowel disease in Korea has been rapidly increasing in recent years. One quarter of the new IBD patients has been known to be presented in childhood. Growth and pubertal delay are one of key factors in the management of pediatric IBD. The focus of treatment in children should be to reduce or eliminate symptoms, optimize nutritional status and growth, and prevent complications. This review will deal with the evidence supporting the treatments currently used in children with inflammatory bowel disease.

Figures and Tables

Table 1
Summary of dosage, indications, and side effects of drugs for the treatment of inflammatory bowel disease in children

Abbreviations; CD: Crohn's disease, UC: Ulcerative colitis


1. Kim BJ, Song SM, Kim KM, Lee YJ, Rhee KW, Jang JY, Park SJ, Yoon CH. Characteristics and trends in the incidence of inflammatory bowel disease in Korean children: A single-center experience. Dig Dis Sci. 2009. (Epub ahead of print).
2. Suh HA, Kim SE, Jang JY, Kim BJ, Kim JS, Lee SY, Chang SH, Kim KM. Efficacy of nutritional therapy in children with Crohn disease. Korean J Pediatr Gastroenterol Nutr. 2006. 9:210–217.
3. Kim KM. The treatment of pediatric inflammatory bowel disease. Korean J Pediatr Gastroenterol Nutr. 2008. 11:S. 72–79.
4. Song SM, Jang JY, Kim KM. Nutritional status of childhood onset inflammatory bowel disease. Clinical Nutrition. 2008. 196(A).
Similar articles